Volume 19, Issue 7
Research Article

Re‐calculating the sample size in internal pilot study designs with control of the type I error rate

Meinhard Kieser

Corresponding Author

E-mail address: Meinhard.Kieser@Schwabe.de

Department of Biometry, Dr. Willmar Schwabe Pharmaceuticals, Willmar‐Schwabe‐Str. 4, 76227 Karlsruhe, Germany

Department of Biometry, Dr. Willmar Schwabe Pharmaceuticals, Willmar‐Schwabe‐Str. 4, 76227 Karlsruhe, GermanySearch for more papers by this author
Tim Friede

Department of Medical Biometry, University of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany

Search for more papers by this author

Abstract

When designing a clinical trial, there is usually some uncertainty about the variability of the primary outcome variable. This may lead to an unnecessarily high or inadequately low sample size. The internal pilot study approach uses data from patients recruited up to an interim stage to re‐estimate the variance and to re‐calculate the final sample size accordingly. Previously, simulation studies have shown that this methodology may highly improve the chance to obtain a well‐powered trial. However, it also turned out that the type I error rate may be inflated by this procedure. We quantify the maximum excess of the type I error rate for normally distributed outcomes. If strict control of the α‐level is considered to be an important issue, a method is proposed to achieve this when re‐calculating the sample size in internal pilot studies. The characteristics of the power distributions are investigated for various sample size adaptation rules and implications are discussed. Copyright © 2000 John Wiley & Sons, Ltd.

Number of times cited according to CrossRef: 82

  • Malaria in the third trimester and maternal‐perinatal outcome, International Journal of Gynecology & Obstetrics, 10.1002/ijgo.13261, 151, 1, (103-108), (2020).
  • Novel Clinical Trial Designs to Improve the Efficiency of Research, Anesthesiology, 10.1097/ALN.0000000000002989, 132, 1, (69-81), (2020).
  • Toi Même: A mHealth Platform for Measuring Bipolar Illness Activity – Feasibility Study Protocol (Preprint), JMIR Research Protocols, 10.2196/18818, (2020).
  • Outcome of pregnancies among women with sickle cell disease, The Journal of Maternal-Fetal & Neonatal Medicine, 10.1080/14767058.2020.1743657, (1-5), (2020).
  • Triple-low Alerts Do Not Reduce Mortality, Anesthesiology, 10.1097/ALN.0000000000002480, 130, 1, (72-82), (2019).
  • Blinded sample size reestimation in event‐driven clinical trials: Methods and an application in multiple sclerosis, Pharmaceutical Statistics, 10.1002/pst.1927, 18, 3, (351-365), (2019).
  • Factors associated with the resumption of sexual intercourse before the scheduled six-week postpartum visit, Tropical Doctor, 10.1177/0049475519855294, (004947551985529), (2019).
  • Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial, Therapeutic Innovation & Regulatory Science, 10.1177/2168479019831240, (216847901983124), (2019).
  • Outcome of pregnancies with marginal umbilical cord insertion, The Journal of Maternal-Fetal & Neonatal Medicine, 10.1080/14767058.2019.1628206, (1-5), (2019).
  • Pap smear accuracy for the diagnosis of cervical precancerous lesions, Tropical Doctor, 10.1177/0049475518798532, 49, 1, (34-39), (2018).
  • Balanced 10% hydroxyethyl starch compared with balanced 6% hydroxyethyl starch and balanced crystalloid using a goal-directed hemodynamic algorithm in pancreatic surgery, Medicine, 10.1097/MD.0000000000010579, 97, 17, (e0579), (2018).
  • Knowledge, attitudes and practices of health personnel of maternities in the prevention of mother-to-child transmission of HIV in a sub-Saharan African region with high transmission rate: some solutions proposed, BMC Pregnancy and Childbirth, 10.1186/s12884-018-1876-0, 18, 1, (2018).
  • Sample Size Reassessment in Non-inferiority Trials, Methods of Information in Medicine, 10.3414/ME09-01-0063, 50, 03, (237-243), (2018).
  • Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure, Statistical Methods in Medical Research, 10.1177/0962280218776991, (096228021877699), (2018).
  • Research Fundamentals: Study Design, Population, and Sample Size, Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal, 10.26685/urncst.16, 2, 1, (1-7), (2018).
  • Internal pilot design for balanced repeated measures, Statistics in Medicine, 10.1002/sim.7524, 37, 3, (375-389), (2017).
  • Adaptive Trial Designs, Clinical Trials Design in Operative and Non Operative Invasive Procedures, 10.1007/978-3-319-53877-8, (99-107), (2017).
  • Can the quality and clinical relevance of Equine Veterinary Journal publications be improved? A time for reflection and refinement, Equine Veterinary Journal, 10.1111/evj.12660, 49, 2, (135-137), (2017).
  • Blinded sample size re‐estimation in three‐arm trials with ‘gold standard’ design, Statistics in Medicine, 10.1002/sim.7356, 36, 23, (3636-3653), (2017).
  • Adaptive Designs: Terminology and Classification, Drug Information Journal, 10.1177/216847900604000408, 40, 4, (425-435), (2017).
  • Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations, Biometrical Journal, 10.1002/bimj.201500233, 59, 2, (344-357), (2016).
  • Blinded sample size recalculation in clinical trials with binary composite endpoints, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2016.1198371, 27, 4, (705-715), (2016).
  • A Two-Stage Adaptive Targeted Clinical Trial Design for Biomarker Performance-Based Sample Size Re-Estimation, Statistics in Biosciences, 10.1007/s12561-015-9139-3, 8, 1, (66-76), (2016).
  • Adaptive Group Sequential Tests, Group Sequential and Confirmatory Adaptive Designs in Clinical Trials, 10.1007/978-3-319-32562-0_6, (133-169), (2016).
  • Trial of Labor After Cesarean Section Among Women with Unique Lower Segment Scarred Uterus and Fetal Weight >3500 g: Prognostic Factors for a Safe Vaginal Delivery, The Journal of Obstetrics and Gynecology of India, 10.1007/s13224-015-0835-1, 66, S1, (202-206), (2016).
  • Distribution of the two‐sample t‐test statistic following blinded sample size re‐estimation, Pharmaceutical Statistics, 10.1002/pst.1737, 15, 3, (208-215), (2016).
  • Flexible Interim Analyses in Clinical Trials Using Multistage Adaptive Test Designs, Drug Information Journal, 10.1177/009286150103500410, 35, 4, (1131-1146), (2016).
  • Sample Size Adjustment in Clinical Trials for Proving Equivalence, Drug Information Journal, 10.1177/009286150103500436, 35, 4, (1401-1408), (2016).
  • Twenty‐five years of confirmatory adaptive designs: opportunities and pitfalls, Statistics in Medicine, 10.1002/sim.6472, 35, 3, (325-347), (2015).
  • Blinded sample size re‐estimation in crossover bioequivalence trials, Pharmaceutical Statistics, 10.1002/pst.1617, 13, 3, (157-162), (2014).
  • Operator Radiation Exposure and Physical Discomfort During a Right Versus Left Radial Approach for Coronary Interventions, JACC: Cardiovascular Interventions, 10.1016/j.jcin.2013.11.026, 7, 7, (810-816), (2014).
  • Blinded sample size re‐estimation in superiority and noninferiority trials: bias versus variance in variance estimation, Pharmaceutical Statistics, 10.1002/pst.1564, 12, 3, (141-146), (2013).
  • Blinded and unblinded internal pilot study designs for clinical trials with count data, Biometrical Journal, 10.1002/bimj.201200189, 55, 4, (617-633), (2013).
  • Methods of Determining Sample Sizes, Sample Size Determination and Power, undefined, (17-55), (2013).
  • Sample Size Re-estimation in Clinical Trials: Overview of Methods and the Statistical View Points to Consider, Japanese Journal of Biometrics, 10.5691/jjb.33.77, 33, 1, (77-99), (2012).
  • Pilot Randomized Trials: Is There a Need?, The Journal of Bone and Joint Surgery-American Volume, 10.2106/JBJS.L.00180, 94, Suppl 1, (15-18), (2012).
  • Optimal sampling in retrospective logistic regression via two‐stage method, Biometrical Journal, 10.1002/bimj.200900253, 53, 1, (5-18), (2011).
  • Bibliography, Adaptive Design Methods in Clinical Trials, Second Edition, 10.1201/b11505-19, (329-350), (2011).
  • A tutorial on pilot studies: the what, why and how, BMC Medical Research Methodology, 10.1186/1471-2288-10-1, 10, 1, (2010).
  • Internal pilots for observational studies, Biometrical Journal, 10.1002/bimj.201000050, 52, 5, (590-603), (2010).
  • Understanding the FDA Guidance on Adaptive Designs: Historical, Legal, and Statistical Perspectives, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2010.514462, 20, 6, (1178-1219), (2010).
  • Sequential Methods in Multi-Arm Clinical Trials, Sequential Analysis, 10.1080/07474946.2010.487416, 29, 4, (444-462), (2010).
  • Blinded Sample Size Recalculation in Noninferiority Trials: A Case Study in Dermatology, Drug Information Journal, 10.1177/009286151004400507, 44, 5, (599-607), (2010).
  • Multisite Trial on Efficacy of Constraint-Induced Movement Therapy in Children with Hemiplegia, American Journal of Physical Medicine & Rehabilitation, 10.1097/PHM.0b013e3181951382, 88, 3, (216-230), (2009).
  • Bibliography, Sample Sizes for Clinical Trials, 10.1201/9781584887409, (277-284), (2009).
  • Sample size re‐estimation in clinical trials, Biometrical Journal, 10.1002/bimj.200800266, 51, 2, (348-357), (2009).
  • Prospective Randomized Study of Early Pulmonary Evaluation of Patients Scheduled for Aortic Valve Surgery Performed by Ministernotomy or Total Median Sternotomy, Journal of Cardiothoracic and Vascular Anesthesia, 10.1053/j.jvca.2009.03.011, 23, 6, (795-801), (2009).
  • Re‐estimating the sample size of an on‐going blinded trial based on the method of randomization block sums, Statistics in Medicine, 10.1002/sim.3442, 28, 1, (24-38), (2008).
  • A SAS macro for sample size adjustment and randomization test for internal pilot study, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2007.11.016, 90, 1, (66-88), (2008).
  • Statistical Issues Including Design and Sample Size Calculation in Thorough QT/QTc Studies∗, Journal of Biopharmaceutical Statistics, 10.1080/10543400802020938, 18, 3, (451-467), (2008).
  • Adaptive Clinical Trials, Drugs in R & D, 10.2165/00126839-200809040-00003, 9, 4, (229-242), (2008).
  • Sequential design approaches for bioequivalence studies with crossover designs, Pharmaceutical Statistics, 10.1002/pst.294, 7, 4, (245-262), (2007).
  • Practical Methods for Bounding Type I Error Rate with an Internal Pilot Design, Communications in Statistics - Theory and Methods, 10.1080/03610920601143634, 36, 11, (2143-2157), (2007).
  • Adaptive Seamless Designs: Selection and Prospective Testing of Hypotheses, Journal of Biopharmaceutical Statistics, 10.1080/10543400701645215, 17, 6, (1135-1161), (2007).
  • Blinded Sample Size Reestimation in Non‐Inferiority Trials with Binary Endpoints, Biometrical Journal, 10.1002/bimj.200610373, 49, 6, (903-916), (2007).
  • Internal pilots for a class of linear mixed models with Gaussian and compound symmetric data, Statistics in Medicine, 10.1002/sim.2840, 26, 22, (4083-4099), (2007).
  • A 25‐year review of sequential methodology in clinical studies, Statistics in Medicine, 10.1002/sim.2763, 26, 2, (237-252), (2006).
  • Increasing the sample size during clinical trials with t‐distributed test statistics without inflating the type I error rate, Statistics in Medicine, 10.1002/sim.2725, 26, 12, (2449-2464), (2006).
  • Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group, Pharmaceutical Statistics, 10.1002/pst.206, 5, 1, (61-66), (2006).
  • A Consultant's Perspective on the Regulatory Hurdles to Adaptive Trials, Biometrical Journal, 10.1002/bimj.200610249, 48, 4, (604-608), (2006).
  • Confirmatory Clinical Trials with an Adaptive Design, Biometrical Journal, 10.1002/bimj.200510239, 48, 4, (574-585), (2006).
  • Sample Size Recalculation in Internal Pilot Study Designs: A Review, Biometrical Journal, 10.1002/bimj.200510238, 48, 4, (537-555), (2006).
  • An Overview of Statistical Approaches for Adaptive Designs and Design Modifications, Biometrical Journal, 10.1002/bimj.200510234, 48, 4, (507-520), (2006).
  • The reassessment of trial perspectives from interim data—a critical view, Statistics in Medicine, 10.1002/sim.2180, 25, 1, (23-36), (2005).
  • Two-Stage Sample Size Re-Estimation Based on a Nuisance Parameter: A Review, Journal of Biopharmaceutical Statistics, 10.1081/BIP-200062852, 15, 4, (559-574), (2005).
  • Variance Estimation in Clinical Studies with Interim Sample Size Reestimation, Biometrics, 10.1111/j.1541-0420.2005.00315.x, 61, 2, (355-361), (2005).
  • Stopping clinical trials by design, Nature Reviews Drug Discovery, 10.1038/nrd1553, 3, 11, (973-977), (2004).
  • The advantages and disadvantages of adaptive designs for clinical trials, Drug Discovery Today, 10.1016/S1359-6446(04)03023-5, 9, 8, (351-357), (2004).
  • Design and analysis of pilot studies: recommendations for good practice, Journal of Evaluation in Clinical Practice, 10.1111/j..2002.384.doc.x, 10, 2, (307-312), (2004).
  • Sample sizes for clinical trials with Normal data, Statistics in Medicine, 10.1002/sim.1783, 23, 12, (1921-1986), (2004).
  • Sample size recalculation for binary data in internal pilot study designs, Pharmaceutical Statistics, 10.1002/pst.140, 3, 4, (269-279), (2004).
  • Controlling Test Size While Gaining the Benefits of an Internal Pilot Design, Biometrics, 10.1111/j.0006-341X.2001.00625.x, 57, 2, (625-631), (2004).
  • Interim Analysis and Sample Size Reassessment, Biometrics, 10.1111/j.0006-341X.2000.01170.x, 56, 4, (1170-1176), (2004).
  • Practical midcourse sample size modification in clinical trials, Controlled Clinical Trials, 10.1016/S0197-2456(02)00240-4, 24, 1, (4-15), (2003).
  • Simple procedures for blinded sample size adjustment that do not affect the type I error rate, Statistics in Medicine, 10.1002/sim.1585, 22, 23, (3571-3581), (2003).
  • Properties of internal pilots with the univariate approach to repeated measures, Statistics in Medicine, 10.1002/sim.1466, 22, 15, (2469-2485), (2003).
  • Blinded sample size reassessment in non‐inferiority and equivalence trials, Statistics in Medicine, 10.1002/sim.1456, 22, 6, (995-1007), (2003).
  • Common threads between sample size recalculation and group sequential procedures, Pharmaceutical Statistics, 10.1002/pst.68, 2, 4, (263-271), (2003).
  • Sample size re‐estimation in cluster randomization trials, Statistics in Medicine, 10.1002/sim.1121, 21, 10, (1337-1350), (2002).
  • A comparison of methods for adaptive sample size adjustment, Statistics in Medicine, 10.1002/sim.972, 20, 24, (3861-3873), (2001).
  • Current and future challenges in the design and analysis of cluster randomization trials, Statistics in Medicine, 10.1002/sim.1115, 20, 24, (3729-3740), (2001).
  • Basic concepts of group sequential and adaptive group sequential test procedures, Statistical Papers, 10.1007/BF02925923, 41, 3, (253-279), (2000).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.